Harbin Gloria Pharmaceuticals (002437) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.084x

Based on the latest financial reports, Harbin Gloria Pharmaceuticals (002437) has a cash flow conversion efficiency ratio of 0.084x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥182.89 Million ≈ $26.76 Million USD) by net assets (CN¥2.18 Billion ≈ $318.68 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Harbin Gloria Pharmaceuticals - Cash Flow Conversion Efficiency Trend (2007–2024)

This chart illustrates how Harbin Gloria Pharmaceuticals's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 002437 total debt and obligations for a breakdown of total debt and financial obligations.

Harbin Gloria Pharmaceuticals Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Harbin Gloria Pharmaceuticals ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Veken Elite SHG:600152	0.043x
Zhejiang JW Precision Machinery Co.Ltd SHE:300984	0.004x
TTW Public Company Limited BK:TTW	0.045x
TTW Public Company Limited BK:TTW-R	0.043x
Jiangsu Libert Inc SHG:605167	0.005x
Cangzhou Dahua Co Ltd SHG:600230	0.018x
Beijing Haitian Ruisheng Science Technology Ltd SHG:688787	0.019x
ABOUT YOU Holding AG F:YOU	-0.403x

Annual Cash Flow Conversion Efficiency for Harbin Gloria Pharmaceuticals (2007–2024)

The table below shows the annual cash flow conversion efficiency of Harbin Gloria Pharmaceuticals from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Harbin Gloria Pharmaceuticals.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥1.97 Billion ≈ $288.69 Million	CN¥410.94 Million ≈ $60.13 Million	0.208x	+29.93%
2023-12-31	CN¥1.71 Billion ≈ $250.26 Million	CN¥274.18 Million ≈ $40.12 Million	0.160x	+4.39%
2022-12-31	CN¥1.70 Billion ≈ $249.28 Million	CN¥261.62 Million ≈ $38.28 Million	0.154x	+10.84%
2021-12-31	CN¥1.98 Billion ≈ $289.58 Million	CN¥274.18 Million ≈ $40.12 Million	0.139x	+1998.19%
2020-12-31	CN¥1.93 Billion ≈ $282.85 Million	CN¥12.76 Million ≈ $1.87 Million	0.007x	-98.28%
2019-12-31	CN¥1.59 Billion ≈ $232.45 Million	CN¥610.37 Million ≈ $89.32 Million	0.384x	+45.20%
2018-12-31	CN¥4.39 Billion ≈ $642.95 Million	CN¥1.16 Billion ≈ $170.15 Million	0.265x	+72.66%
2017-12-31	CN¥4.25 Billion ≈ $622.28 Million	CN¥651.80 Million ≈ $95.38 Million	0.153x	-40.39%
2016-12-31	CN¥4.05 Billion ≈ $592.15 Million	CN¥1.04 Billion ≈ $152.26 Million	0.257x	+27.19%
2015-12-31	CN¥3.47 Billion ≈ $508.18 Million	CN¥702.05 Million ≈ $102.73 Million	0.202x	-6.96%
2014-12-31	CN¥3.10 Billion ≈ $453.95 Million	CN¥674.04 Million ≈ $98.63 Million	0.217x	+18.87%
2013-12-31	CN¥2.48 Billion ≈ $362.66 Million	CN¥453.02 Million ≈ $66.29 Million	0.183x	+109.59%
2012-12-31	CN¥2.36 Billion ≈ $345.46 Million	CN¥205.89 Million ≈ $30.13 Million	0.087x	+49.01%
2011-12-31	CN¥2.20 Billion ≈ $321.54 Million	CN¥128.61 Million ≈ $18.82 Million	0.059x	+10.24%
2010-12-31	CN¥2.12 Billion ≈ $310.33 Million	CN¥112.59 Million ≈ $16.48 Million	0.053x	-91.06%
2009-12-31	CN¥287.53 Million ≈ $42.07 Million	CN¥170.82 Million ≈ $25.00 Million	0.594x	+99.41%
2008-12-31	CN¥194.04 Million ≈ $28.39 Million	CN¥57.81 Million ≈ $8.46 Million	0.298x	-21.12%
2007-12-31	CN¥138.36 Million ≈ $20.25 Million	CN¥52.26 Million ≈ $7.65 Million	0.378x	--

About Harbin Gloria Pharmaceuticals

SHE:002437 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.15 Billion

CN¥7.86 Billion CNY

Market Cap Rank

#8518 Global

#2214 in China

Share Price

CN¥3.52

Change (1 day)

-2.76%

52-Week Range

CN¥2.44 - CN¥4.04

All Time High

CN¥11.06